Pharmacy Law – A Focus on Opioid Prescriptions

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

From 1999 to 2017, more than 700,000 people died in the United States from a drug overdose. About 400,000 of these deaths involved both prescription and illicit opioids (eg, heroin); 218,000 deaths involved prescription opioids. In 2017 alone, there were more than 70,000 overdose deaths, with nearly 70% involving opioids. This was a 10% increase from 2016, when there were 63,632 overdose deaths and two-thirds involved opioids.

The current rise in opioid overdose deaths can be described in three distinct phases. The first phase began in 1999 following an increase in the prescribing of opioids during the 1990s, due in part to a new, patient-centered focus on relieving pain as the 5th vital sign. The second phase began in 2010, with rapid increases in overdose deaths involving heroin. The third phase began in 2013, with significant increases in overdose deaths involving synthetic opioids (eg, tramadol, fentanyl), especially illicitly manufactured fentanyl. Although the opioid overdose epidemic has evolved and worsened in recent years, provisional data from 2018 indicates potential improvements in some overdose indicators. However, a final analysis will be necessary to confirm this change.

Since 2012, opioid prescribing rates have declined, suggesting that prescribers have become more cautious in their prescribing practices. However, prescriptions for opioids continue to contribute to the epidemic, with more than 35% of all opioid overdose deaths specifically involving prescription opioids. Prescription opioid use is a risk factor for illicit drug abuse, such as with heroin or fentanyl. Evidence suggests that most individuals became addicted to illicit opioids after using prescription opioids…

Issue Overview

More To Explore

What is The Rx Consultant?

The Rx Consultant is a subscription-based service that delivers practical updates & reviews covering all the top-selling drugs and common health conditions. All our publications focus on the facts busy front-line pharmacists and other health care practitioners need to stay current, and provide it a streamlined, easy reading style.

For 30 years The Rx Consultant has operated independent of the pharmaceutical industry and has no commercial bias.

Join thousands of healthcare providers who enjoy the following benefits every month.

1. Drug Therapy Updates & Reviews

The eLibrary contains over 30 streamlined updates on drug therapy for the most common diseases. New articles are added every month – it is a continually expanding resource.

2. Continuing Education

The eLibrary includes 50+ hours of Pharmacology CE from an ACPE approved provider at no additional charge. Each article provides at least 1.5 hours of Pharmacology CE. Subscribers can take their tests online, score them immediately, then print or save their credit statements. Pharmacology CE tests can also be mailed, faxed, or even phoned in to The Rx Consultant office, and credit statements will be delivered by mail or fax.

3. Unlimited Access to our Resource Library, with:

  • Healthcare News

    The eLibrary includes a news column covering the developments that matter most to nurse practitioners and other front-line providers. You get a headline, the bottom line, and how it’s likely to affect your practice in a few short lines, then it’s on to the next news item. The news briefs are also available in print monthly as Rx News Connection.
  • Patient Education Pages

    Patient Q&A to sharpen your skills in educating patients and answering common questions.
  • Charts & Tables

    At-a-glance updates on drugs, doses, common side effects & interactions
  • Quick Facts

    Key facts organized for fast access both online and on handy reference cards.
  • The Bottom Line

    Our members suggest the topics and each issue undergoes a rigorous three month peer reviewed process. Our CE is different because we accept no grants, advertising, or funding of any kind from drug manufacturers. With no financial ties, maintaining a bias-free publication is a straightforward process.

The Rx Consultant maintains a high standard for quality

And a rigorous system for content development that insures it. Every issue is written by an expert in the topic area, and then peer reviewed, fact-checked and edited to insure that the content is

  • Evidence-based
  • Non-Biased
  • Balanced
  • Timely
  • Accurate and
  • Useful for community practitioners

The Rx Consultant is completely independent of the pharmaceutical industry.

We accept no grants, advertising, or funding of any kind from drug manufacturers. With no financial ties, maintaining a bias-free publication is a straightforward process.